Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Emergency medical consultations share with other emergencies the need for prompt action, potentially without information or tools ordinarily available.
AMA J Ethics. 2016;18(5):479-484. doi:
10.1001/journalofethics.2016.18.5.ecas1-1605.
Framing discussions of ALS around the disease rather than the psychologically complex person with the disease focuses attention on symptoms and imagined outcomes rather than patients’ coping strategies and quality of life.
AMA J Ethics. 2015;17(6):530-534. doi:
10.1001/journalofethics.2015.17.6.nlit2-1506.